title: Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase.
abstract: Direct binding of apolipoprotein (apo)B-containing lipoproteins to proteoglycans is the initiating event in atherosclerosis, but the processes involved at later stages of development are unclear. Here, we investigated the importance of the apoB-proteoglycan interaction in the development of atherosclerosis over time and investigated the role of lipoprotein lipase (LPL) to facilitate low-density lipoprotein (LDL) retention at later stages of development. Atherosclerosis was analyzed in apoB transgenic mice expressing LDL with normal (control LDL) or reduced proteoglycan-binding (RK3359-3369SA LDL) activity after an atherogenic diet for 0 to 40 weeks. The initiation of atherosclerosis was delayed in mice expressing RK3359-3369SA LDL, but they eventually developed the same level of atherosclerosis as mice expressing control LDL. Retention studies in vivo showed that although higher levels of 131I-tyramine cellobiose-labeled control LDL (131I-TC-LDL) were retained in nonatherosclerotic aortae compared with RK3359-3369SA 131I-TC-LDL, the retention was significantly higher and there was no difference between the groups in atherosclerotic aortae. Lower levels of control 125I-TC-LDL and RK3359-3369SA 125I-TC-LDL were retained in atherosclerotic aortae from ldlr-/- mice transplanted with lpl-/- compared with lpl+/+ bone marrow. Uptake of control LDL or RK3359-3369SA LDL into macrophages with specific expression of human catalytically active or inactive LPL was increased compared with control macrophages. Furthermore, transgenic mice expressing catalytically active or inactive LPL developed the same extent of atherosclerosis. Thus, retention of LDL in the artery wall is initiated by direct LDL-proteoglycan binding but shifts to indirect binding with bridging molecules such as LPL.
authors.affiliation: Sahlgrenska Center for Cardiovascular and Metabolic Research/Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Göteborg University, Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Gustafsson
authors.forename: Malin
authors.initials: M
authors.lastname: Levin
authors.forename: Kristina
authors.initials: K
authors.lastname: Skålén
authors.forename: Jeanna
authors.initials: J
authors.lastname: Perman
authors.forename: Vincent
authors.initials: V
authors.lastname: Fridén
authors.forename: Pernilla
authors.initials: P
authors.lastname: Jirholt
authors.forename: Sven-Olof
authors.initials: SO
authors.lastname: Olofsson
authors.forename: Sergio
authors.initials: S
authors.lastname: Fazio
authors.forename: MacRae F
authors.initials: MF
authors.lastname: Linton
authors.forename: Clay F
authors.initials: CF
authors.lastname: Semenkovich
authors.forename: Gunilla
authors.initials: G
authors.lastname: Olivecrona
authors.forename: Jan
authors.initials: J
authors.lastname: Borén
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008071:Lipoprotein Lipase / Q000502:physiology*; D008077:Lipoproteins, LDL / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011485:Protein Binding / Q000235:genetics
chemical_list: D008077:Lipoproteins, LDL; D008071:Lipoprotein Lipase